Bone Morphogenetic Protein Signaling in Skeletal Development

Bone morphogenetic proteins (BMPs) are secreted growth factors belonging to the transforming growth factor-β superfamily that orchestrate the formation, growth and maintenance of the vertebrate skeleton. During embryogenesis, BMPs establish gradients that govern the commitment of mesenchymal stem cells to chondrocyte and osteoblast lineages, promoting cartilage template formation and subsequent ossification. Ligand binding to heterotetrameric BMP type I and II receptors activates intracellular SMAD-dependent pathways, in which receptor-activated SMADs partner with SMAD4 to regulate transcription of key osteogenic and chondrogenic genes. Parallel SMAD-independent cascades—such as p38 MAP kinase—further fine-tune cellular proliferation, differentiation and apoptosis. Extracellular antagonists, including noggin and chordin, modulate BMP ligand availability, while intracellular ubiquitin-mediated mechanisms govern receptor turnover and SMAD activity. Crosstalk with Wnt, Hedgehog and fibroblast growth factor pathways integrates BMP signals into broader developmental networks. Postnatally, BMP signalling continues to regulate bone remodelling by balancing osteoblast-mediated bone formation against osteoclast-mediated resorption. Dysregulation of BMP signalling underlies a range of congenital and acquired skeletal disorders, from fibrodysplasia ossificans progressiva to osteoporosis, and informs tissue-engineering approaches for fracture repair and spinal fusion. Advances in receptor-specific agonists, ligand traps and small-molecule modulators hold promise for refined clinical interventions across paediatric and adult bone diseases.

Research from Nature Portfolio

Recent work has elucidated the cell-specific role of the BMP type I receptor BMPR1A in hyperthyroidism-induced bone loss. Conditional deletion of BMPR1A in osteoprogenitor cells protected mice from thyroid hormone-driven osteoporosis by preventing the rise in RANKL/OPG ratio that normally accelerates osteoclastic resorption. In contrast, ablation of BMPR1A in osteoclast precursors failed to mitigate bone loss, demonstrating that osteoblastic BMP signalling is the principal driver of hormone-coupled bone turnover. These findings underscore the potential of targeting BMPR1A in osteoblasts to uncouple pathological bone resorption from systemic endocrine stimuli.

Bone Morphogenetic Protein Signaling in Skeletal Development publication trend

The graph below shows the total number of articles in bone morphogenetic protein signaling in skeletal development across all publications each year (not limited to Nature Index journals).

Technical terms

Bone morphogenetic proteins (BMPs): Secreted cytokines of the TGF-β superfamily that induce bone and cartilage formation.

SMAD proteins: Intracellular transcription factors that convey signals from activated BMP receptors to the nucleus.

BMPR1A: A type I BMP receptor essential for osteoblast differentiation and skeletal patterning.

Osteoblasts: Cells responsible for bone matrix synthesis and mineral deposition.

Osteoclasts: Multinucleated cells that resorb mineralised bone during remodelling.

Chondrogenesis: The developmental process by which cartilage is formed from mesenchymal progenitors.

Osteogenesis: The formation of new bone tissue through coordinated osteoblast activity and matrix mineralisation.

References

1. The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease. Cell Research (2024).
2. Hyperthyroidism-driven bone loss depends on BMP receptor Bmpr1a expression in osteoblasts. Communications Biology (2024).
3. Activin receptor-like kinase 3: a critical modulator of development and function of mineralized tissues. Frontiers in Cell and Developmental Biology (2023).
4. The Smad Dependent TGF-β and BMP Signaling Pathway in Bone Remodeling and Therapies. Frontiers in Molecular Biosciences (2021).